Historians may look back on May 8, 2006, as a turning point in the history of molecular imaging. Before then, FDG-PET was chronically tangled in political problems that slowed its entry into the clinical mainstream.
Historians may look back on May 8, 2006, as a turning point in the history of molecular imaging. Before then, FDG-PET was chronically tangled in political problems that slowed its entry into the clinical mainstream. But in May, as the result of an unusual collaboration, Medicare payment took effect for most applications of FDG-PET and PET/CT in oncology.
At the same time the payment plan launched, a national PET registry was implemented to monitor the effect of the new indications on clinical decision making and patient management.
The payment policy includes 114 new indications spanning diagnosis, staging, and restaging. For the first time, Medicare will also provide payment for treatment monitoring of nearly every type of cancer.
But payment is contingent upon mandatory participation in a two-year survey managed by the American College of Radiology Imaging Network. Referring physicians must complete pre- and postimaging surveys in order to qualify a procedure for reimbursement. As of the middle of May 2006, the registry included 701 participants.
Results of large clinical trials in the first half of 2006 suggest that several molecular-based MR applications are also poised to enter the mainstream. The multicenter Magnetic Resonance Imaging for Breast Cancer Screening Trial confirmed the value of dynamic contrast-enhanced MRI as a screening tool for middle-aged women with genetic susceptibility to breast cancer. At the International Society for Magnetic Resonance in Medicine meeting in May, researchers at Catharina Hospital in Eindhoven, the Netherlands, demonstrated that the lymphotrophic nanoparticle ferumoxtran-10 reliably identifies prostatic lymph node metastases.
The MR tests, performed on 120 presurgical patients and 17 controls in a nonacademic setting, were 89% sensitive and 99% specific for metastastic nodes.
Nanotechnologies are also contributing important basic discoveries among more than 1000 scientific papers on molecular imaging published in the past six months. A basic scientific session on novel contrast media at the ISMRM meeting attracted an audience of more than 1200. Big things are expected from recent innovations with these ultrasmall agents.
In one instance, an interdisciplinary research team at the University of California, Los Angeles has demonstrated that miniature, microfluidic integrated circuits can manufacture FDG for PET imaging (Science 2005;310(5766):1793-1786). Large arrays of these "labs-on-a-chip" promise to revolutionize production methods for FDG and other radiopharmaceutical agents, said Dr. Sam Gambhir, director of the molecular imaging program at Stanford University.
At Stanford, researchers are exploring the capability of self-illuminating quantum dots. These are the first nanoparticles that may be used in optical imaging without an external illumination source, thereby greatly increasing sensitivity, according to Gambhir.
The microdot produces light from its R-Luc8 protein through a process called bioluminescence resonance energy transfer. The nanoparticle can potentially report several molecular events simultaneously by emitting light at several frequencies (Nat Biotech 2006; 24(3):339-343).
Concerns about the potential toxicity of carbon nanotubes may diminish because of work conducted at the University of London's Center for Drug Delivery Research. Investigators found that nanoparticles do not dwell in the liver and kidneys as long as suspected, and their circulation profile is ideal for molecular imaging, according to Dr. King Li, associate director of radiology at the National Institutes of Health. The findings will lead to more research exploiting the huge surface receptor and contrast media capacity of this material (PNAS 2006; 103(9):3357-3362).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Current Perspectives on Radiology Workforce Issues and Potential Solutions
March 14th 2024Emphasizing the gravity of the ongoing workforce shortage in radiology, these authors recommend a change agenda focusing on expanded numbers of residency positions, reassessment of educational pathways, maintaining a strong presence in hospital settings and practice level initiatives to reduce administrative burden and achieve appropriate reimbursement beyond RVU measurements.
Could Cloud-Based 'Progressive Loading' be a Boon for Radiology Workflows?
March 13th 2024The newly launched Progressive Loading feature, available through RamSoft’s OmegaAI software, reportedly offers radiologist rapid uploading of images that is faster than on-site networks and other cloud-based systems regardless of the network radiologists are using.